Proteomic strategies in multiple sclerosis and its animal models

Proteomics - Clinical Applications

Volumn 1, Issue 11, 2007, Pages 1393-1405

  Elkabes, Stella ^a   Li, Hong ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoimmune disease; Cerebrospinal fluid; Experimental autoimmune encephalomyelitis; Glia; Spinal cord inflammation

Indexed keywords

AUTOANTIBODY; AUTOTAXIN; BIOLOGICAL MARKER; BRAIN PROTEIN; CARTILAGE ACIDIC PROTEIN; CASPASE 14; COMPLEMENT COMPONENT C3; CONTACTIN 1; HEAT SHOCK PROTEIN 90; LIPOCORTIN 1; LIPOCORTIN 2; NEUREXIN 2 ALPHA PRECURSOR; OSTEONECTIN; SCATTER FACTOR; TETRANECTIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; DEMYELINATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; REPRODUCIBILITY; REVIEW;

ANIMALIA;

EID: 38449089082     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200700315     Document Type: Review

References (129)

1. Frohman, E. M., Havrdova, E., Lublin, F., Barkhof, F. et al., Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 2006, 63, 614-619.
2. Pittock, S. J., Weinshenker, B. G., Noseworthy, J. H., Lucchinetti, C. F. et al., Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 2006, 63, 611-614.
3. Chang, A., Tourtellotte, W. W., Rudick, R., Trapp, B. D., Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346, 165-173.
4. Franklin, R. J., Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 2002, 3, 705-714.
5. Husted, C. A., Goodin, D. S., Hugg., J. W., Maudsley, A. A. et al., Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann. Neurol. 1994, 36, 157-165.
6. Filippi, M., Campi, A., Dousset, V., Baratti, C. et al., A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995, 45, 478-482.
7. Griffin, C. M., Chard, D. T., Parker, G. J., Barker, G. J. et al., The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. 2002, 249, 193-199.
8. Giordana, M. T., Richiardi, P., Trevisan, E., Boghi, A., Palmucci, L., Abnormal ubiquitination of axons in normally myelinated white matter in multiple sclerosis brain. Neuropathol. Appl. Neurobiol. 2002, 28, 36-41.
9. Plumb, J., McQuaid, S., Mirakhur, M., Kirk, J., Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2002, 12, 154-169.
10. Tartaglia, M. C., Narayanan, S., De Stefano, N., Arnaoutelis, R. et al., Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J. Neurol. 2002, 249, 1382-1390.
11. Graumann, U., Reynolds, R., Steck, A. J., Schaeren-Wiemers, N., Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003, 13, 554-573.
12. Sinclair, C., Mirakhur, M., Kirk, J., Farrell, M., McQuaid, S., Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: An immunohistochemical study utilizing tissue microarrays. Neuropathol. Appl. Neurobiol. 2005, 31, 292-303.
13. Davie, C. A., Barker, G. J., Webb, S., Tofts, P. S. et. al., Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995, 118, 1583-1592.
14. De Stefano, N., Matthews, P. M., Fu, L., Narayanan S. et al., Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998, 121, 1469-1477.
15. Fu, L., Matthews, P. M., De Stefano, N., Worsley, K. J. et al., Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121, 103-113.
16. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R. et al., Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278-285.
17. Evangelou, N., Esiri, M. M., Smith, S., Palace, J., Matthews, P. M., Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 2000, 47, 391-395.
18. Wylezinska, M., Cifelli, A., Jezzard, P., Palace, J. et al., Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003, 60, 1949-1954.
19. Rovaris, M., Gambini, A., Gallo, A., Falini, A. et al., Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005, 65, 1626-1630.
20. De Stefano, N., Narayanan, S., Francis, G. S., Arnaoutelis, R. et al., Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 2001, 58, 66-70.
21. Bruck, W., Stadelmann, C., Inflammation and degeneration in multiple sclerosis. Neurol. Sci. 2003, 24, S266-S267.
22. Narayanan, S., Francis, S. J., Sled, J. G., Santos, A. C. et al., Axonal injury in the cerebral normal appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. Neuroimage 2006, 29, 637-642.
23. Kapeller, P., McLean, M. A., Griffin, C. M., Chard, D. et al., Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: A quantitative MR spectroscopic imaging study. J. Neurol. 2001 248, 131-138.
24. Filippi, M., Rocca, M. A., MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J. Neurol. 2005, 252, v16-v24.
25. Valsasina, P., Benedetti., B., Rovaris, M., Sormani, M. P. et al., Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 2005, 65, 1126-1128.
26. Steinman, L., Zamvil, S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60, 12-21.
27. Hu, S., Loo, J. A., Wong, D. T., Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
28. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
29. Robinson, W. H., Fontoura, P., Lee, B. J., de Vegvar, H. E. et al., Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 2003, 21, 1033-1039.
30. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
31. deVera, I. E., Katz, J. E., Agus, D. B., Clinical proteomics: The promises and challenges of mass spectrometry-based biomarker discovery. Clin. Adv. Hematol. Oncol. 2006, 4, 541-549.
32. Tannu, N. S., Hemby, S. E., Methods for proteomics in neuroscience. Prog. Brain Res. 2006, 158, 41-82.
33. Wittmann-Liebold, B., Graack, H. R., Pohl, T., Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 2006, 6, 4688-4703.
34. Wiese, S., Reidegeld, K. A., Meyer, H. E., Warscheid, B., Protein labeling by iTRAQ- A new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7, 340-350.
35. Gorg, A., Weiss, W., Dunn, M. J., Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4, 3666-3685.
36. Mootha, V. K., Bunkenborg, J., Olsen, J. V., Hjerrild, M. et al., Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003, 115, 629-640.
37. Morandell, S., Stasyk, T., Grosstessner-Hain, K., Roitinger, E. et al., Phosphoproteomics strategies for the functional analysis of signal transduction. Proteomics 2006, 6, 4047-4056.
38. Alban, A., David, S. O., Bjorkesten, L., Andersson, C. et al., A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
39. Zhang, K., Wu, S., Tang, X., Kaiser, N. K., Bruce, J. E., A bifunctional monolithic column for combined protein preconcentration and digestion for high throughput proteomics research. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 849, 223-230.
40. Yi, E. C., Li, X. J., Cooke, K., Lee, H. et al., Increased quantitative proteome coverage with (13)C/(12)C-based, acid-cleavable isotope-coded affinity tag reagent and modified data acquisition scheme. Proteomics 2006, 5, 380-387.
41. Aggarwal, K., Choe, L. H., Lee, K. H., Quantitative analysis of protein expression using amine-specific isobaric tags in Escherichia coli cells expressing rhsA elements. Proteomics 2005, 5, 2297-2308.
42. Smith, R. D., Anderson, G. A., Lipton, M. S., Pasa-Tolic, L. et al., An accurate mass tag strategy for quantitative and high-throughput proteome measurements. Proteomics 2002, 2, 513-523.
43. Dumont, D., Noben, J. P., Raus, J., Stinissen, P., Robben, J., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
44. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: Characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
45. You, J. S., Gelfanova, V., Knierman, M. D., Witzmann, F. A. et al., The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005, 5, 290-296.
46. Del Boccio, P., Pieragostino, D., Lugaresi, A., Di Ioia, M. et al., Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 2007, 62, 201-204.
47. Irani, D. N., Anderson, C., Gundry, R., Cotter, R. et al., Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006, 59, 237-247.
48. Hansson, S. F., Hviid Simonsen, A., Zetterberg, H., Andersen, O. et al., Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol. 2007, 62, 193-196.
49. Nakashima, I., Fujinoki, M., Fujihara, K., Kawamura, T. et al., Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann. Neurol. 2007, 62, 197-200.
50. Carrette, O., Burkhard, P. R., Hughes, S., Hochstrasser, D. F., Sanchez, J. C., Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? Proteomics 2005, 5, 3060-3065.
51. Terry, D. E., Desiderio, D. M., Between-gel reproducibility of the human cerebrospinal fluid proteome. Proteomics 2003, 3, 1962-1979.
52. Chong, P. K., Gan, C. S., Pham, T. K., Wright, P. C., Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: Implication of multiple injections. J. Proteome Res. 2006, 5, 1232-1240.
53. Choe, L. H., Aggarwal, K., Franck, Z., Lee, K. H., A comparison of the consistency of proteome quantitation using two-dimensional electrophoresis and shotgun isobaric tagging in Escherichia coli cells. Electrophoresis 2005, 26, 2437-2449.
54. Bielekova, B., Martin, R., Development of biomarkers in multiple sclerosis. Brain 2004, 127, 1463-1478.
55. Elderfield, A. J., Newcombe, J., Bolton, C., Flower, R. J., Lipocortins (annexins) 1, 2, 4 and 5 are increased in the central nervous system in multiple sclerosis. J. Neuroimmunol. 1992, 39, 91-100.
56. Probst-Cousin, S., Kowolik, D., Kuchelmeister, K., Kayser, C. et al., Expression of annexin-1 in multiple sclerosis plaques. Neuropathol. Appl. Neurobiol. 2002, 28, 292-300.
57. Craner, M. J., Lo, A. C., Black, J. A., Baker, D. et al., Annexin II/p11 is up-regulated in Purkinje cells in EAE and MS. Neuroreport 2003, 14, 555-558.
58. Pan, S., Wang, Y., Quinn, J. F., Peskind, E. R. et al., Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J. Proteome Res. 2006, 5, 2769-2779.
59. Black, M. D., Carey, F., Crossman, A. R., Relton, J. K., Rothwell, N. J., Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res. 1992, 585, 135-140.
60. Pitt, D., Werner, P., Raine, C. S., Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6, 87-70.
61. Smith, T., Groom, A., Zhu, B., Turski, L., Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 2000, 6, 62-66.
62. Huitinga, I., Bauer, J., Strijbos, P. J., Rothwell, N. J. et al., Effect of annexin-1 on experimental autoimmune encephalomyelitis (EAE) in the rat. Clin. Exp. Immunol. 1998, 111, 198-204.
63. Siao, C. J., Tsirka, S. E., Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J. Neurosci. 2002, 22, 3352-3358.
64. Kazarinova-Noyes, K., Malhotra, J. D., McEwen, D. P., Mattei, L. N. et al., Contactin associates with Na+ channels and increases their functional expression. J. Neurosci. 2001, 21, 7517-7525.
65. Shah, B. S., Rush, A. M., Liu, S., Tyrrell, L. et al., Contactin associates with sodium channel Nav1.3 in native tissues and increases channel density at the cell surface. J. Neurosci. 2004, 24, 7387-7399.
66. Rush, A. M., Craner, M. J., Kageyama, T., Dib-Hajj, S. D. et al., Contactin regulates the current density and axonal expression of tetrodotoxin-resistant but not tetrodotoxin-sensitive sodium channels in DRG neurons. Eur. J. Neurosci. 2005, 22, 39-49.
67. Waxman, S. G., Craner, M. J., Black, J. A., Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol. Sci. 2004, 25, 584-591.
68. Waxman, S. G., Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat. Rev. Neurosci. 2006, 7, 932-941.
69. Falk, J., Bonnon, C., Girault, J. A., Faivre-Sarrailh, C. F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination. Biol. Cell. 2002, 94, 327-334.
70. Hu, Q. D., Ang, B. T., Karsak, M., Hu, W. P. et al., F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 2003, 115, 163-175.
71. Hu, Q. D., Ma, Q. H., Gennarini, G., Xiao, Z. C., Cross-talk between F3/ contactin and Notch at axoglial interface: A role in oligodendrocyte development. Dev. Neurosci. 2006, 28, 25-33.
72. Stella, M. C., Vercelli, A., Repici. M., Follenzi, A., Comoglio, P. M., Macrophage stimulating protein is a novel neurotrophic factor. Mol. Biol. Cell. 2001, 12, 1341-1352.
73. Schmidt, O., Doxakis, E., Davies, A. M. Macrophage-stimulating protein is a neurotrophic factor for embryonic chicken hypoglossal motoneurons. Eur. J. Neurosci. 2002 15, 101-118.
74. Forgie, A., Wyatt, S., Correll, P. H., Davies, A. M., Macrophage stimulating protein is a target-derived neurotrophic factor for developing sensory and sympathetic neurons, Development 2003, 130, 995-1002.
75. Tsutsui, S., Noorbakhsh, F., Sullivan, A., Henderson, A. J. et al., RON-regulated innate immunity is protective in an animal model of multiple sclerosis. Ann. Neurol. 2005, 57, 883-895.
76. Duzhak, T., Emerson, M. R., Chakrabarty, A., Alterman, M. A., Levine, S, M., Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell Mol. Biol. (Noisy-le-grand) 2003, 49, 723-732.
77. Alt, C., Duvefelt, K., Franzen, B., Yang, Y., Engelhardt, B., Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57BI/6 and SJL mice. Brain Pathol. 2005, 15, 1-16.
78. Liu, T., Donahue, K. C., Hu, J., Kurnellas, M. P. et al., Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6, 2565-2575.
79. Grant, J., Hu, J., Liu, T., Jain, M. et al., Post-translational modifications in the rat lumbar spinal cord in experimental autoimmune encephalomyelitis. J. Proteome Res. 2007, 6, 2786-2791.
80. Nicot, A., Ratnakar, P. V., Ron, Y., Chen, C. C, Elkabes, S., Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain 2003, 126, 398-412.
81. Nicot, A., Kurnellas, M., Elkabes, S. Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis. Eur. J. Neurosci. 2005, 21, 2660-2670.
82. Robinson, W. H., Steinman, L., Utz, P. J. Proteomics technologies for the study of autoimmune disease. Arthritis Rheum. 2002, 46, 885-893.
83. Joos, T. O., Schrenk, M., Hopfl, P., Kroger, K. et al., A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000, 21, 2641-2650.
84. MacBeath, G., Schreiber, S. L., Printing proteins as microarrays for high-throughput function determination. Science 2000, 289, 1760-1763.
85. Haab, B. B., Dunham, M. J., Brown, P. O., Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001, 2, RESEARCH0004.
86. Lobell, A., Weissert, R., Storch, M. K., Svanholm, C. et al., Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 1998, 187, 1543-1548.
87. Youssef, S., Wildbaum, G., Maor, G., Lanir, N. et al., Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 1998, 161, 3870-3879.
88. Bourquin, C., Iglesias, A., Berger, T., Wekerle, H., Linington, C., Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2000, 30, 3663-3671.
89. Selmaj, K., Kowal, C., Walczak, A., Nowicka, J., Raine, C. S., Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 111, 34-44.
90. Wildbaum, G., Netzer, N., Karin, N., Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 2002, 168, 5885-5892.
91. Lobell, A., Weissert, R., Eltayeb, S., de Graaf, K. L. et al., Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol. 2003, 170, 1805-1813.
92. Kanter, J. L., Narayana, S., Ho, P. P, Catz, I. et al., Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 2006, 12, 138-143.
93. Ilyas, A. A, Chen, Z. W, Cook, S. D. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 2003, 139, 76-80.
94. Rosenbluth, J., Schiff, R., Liang, W. L., Dou, W., Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J. Neurocytol. 2003, 32, 265-276.
95. Rosenbluth, J., Moon, D., Dysmyelination induced in vitro by IgM antisulfatide and antigalactocerebroside monoclonal antibodies. J. Neurosci. Res. 2003, 71, 104-119.
96. Halder, R. C, Jahng, A., Maricic, I., Kumar, V., Mini review: Immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem. Res. 2007, 32, 257-262.
97. Somers, V., Govarts, C., Hellings, N., Hupperts, R., Stinissen, P., Profiling the autoantibody repertoire by serological antigen selection. J. Autoimmun. 2005, 25, 223-228.
98. Hufton, S. E., Moerkerk, P. T., Meulemans, E. V., de Bruine, A. et al., Phage display of cDNA repertoires: The pVI display system and its applications for the selection of immunogenic ligands. J. Immunol. Methods 1999, 231, 39-51.
99. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B. et al., Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47, 707-717.
100. Cortese, I., Tafi, R., Grimaldi, L. M., Martino, G. et al., Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc. Natl. Acad. Sci. USA 1996, 93, 11063-11067.
101. Cortese, I., Capone, S., Tafi, R. et al., Identification of peptides binding to IgG in the CSF of multiple sclerosis patients. Mult. Scler. 1998, 4, 31-36.
102. Cortese, I., Capone, S., Luchetti, S., Grimaldi, L. M. et al., CSF-enriched antibodies do not share specificities among MS patients. Mult. Scler. 1998, 4, 118-123.
103. Jensen, N. A., Celis, J. E., Proteomic changes associated with degeneration of myelin-forming cells in the central nervus system of c-myc transgenic mice. Electrophoresis 1998, 19, 2014-2020.
104. Colello, R. J., Fuss, B., Fox, M. A., Alberti. J., A proteomic approach to rapidly elucidate oligodendrocyte-associated proteins expressed in the myelinating rat optic nerve. Electrophoresis 2001, 23, 144-151.
105. Marta, C. B., Montano, M. B., Taylor, C. M., Taylor, A. L. et al., Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: Potential implications for multiple sclerosis. J. Biol. Chem. 2005, 280, 8985-8993.
106. Vanrobaeys, F., Van Coster, R., Dhondt, G., Devreese, B., Van Beeumen, J., Profiling of myelin proteins by 2D-gel electrophoresis and multidimensional liquid chromatography coupled to MALDI TOF-TOF mass spectrometry. J. Proteome Res. 2005, 4, 2283-2293.
107. Genain, C. P., Cannella, B., Hauser, S. L., Raine, C. S., Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5, 170-175.
108. Raine, C. S., Cannella, B., Hauser, S. L., Genain, C. P., Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann. Neurol. 1999, 46, 144-160.
109. Lassmann, H., Bruck, W., Lucchinetti, C., Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 2001, 7, 115-121.
110. Kornek, B., Lassmann, H., Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 2003, 61, 321-326.
111. Sun, J., Link, H., Olsson, T., Xiao, B. G. et al., T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 1991, 146, 1490-1495.
112. Xiao, B. G., Linington, C., Link, H., Antibodies to myelinoligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J. Neuroimmunol. 1991, 31, 91-96.
113. Markovic, M., Trajkovic, V., Drulovic, J., Mesaros, S. et al., Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients. J. Neurol. Sci. 2003, 211, 67-73.
114. Zhou, D., Srivastava, R., Nessler, S., Grummel, V. et al., Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006, 103, 19057-19062.
115. Marta, C. B., Taylor, C. M., Coetzee, T., Kim, T. et al., Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. J. Neurosci. 2003, 23, 5461-5471.
116. Colello, R. J., Schwab, M. E., A role for oligodendrocytes in the stabilization of optic axon numbers. J. Neurosci. 1994, 14, 6446-6452.
117. Colello, R. J., Pott, U., Schwab, M. E., The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J. Neurosci. 1994, 14, 2594-2605.
118. Hansson, E., Ronnback, L., Glial neuronal signaling in the central nervous system.FASEB J. 2003, 17, 341-348.
119. Schafer, D. P., Rasband, M. N., Glial regulation of the axonal membrane at nodes of Ranvier. Curr. Opin. Neurobiol. 2006, 16, 506-514.
120. Moynagh, P. N., The interleukin-1 signalling pathway in astrocytes: A key contributor to inflammation in the brain. J. Anat. 2005, 207, 265-269.
121. Tani, M., Glabinski, A. R., Tuohy, V. K., Stoler, M. H. et al., In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am. J. Pathol. 1996, 148, 889-896.
122. Van Der Voorn, P., Tekstra, J., Beelen, R. H., Tensen, C. P. et al., Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathol. 1999, 154, 45-51.
123. De Keyser, J., Wilczak, N., Leta, R., Streetland, C., Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999, 53, 1628-1633.
124. Palma, J. P., Kwon, D., Clipstone, N. A., Kim, B. S., Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: Potential role for the initiation of demyelinating disease. J. Virol. 2003, 77, 6322-6331.
125. Yang, J. W., Suder, P., Silberring, J., Lubec, G., Proteome analysis of mouse primary astrocytes. Neurochem. Int. 2005, 47, 159-172.
126. Yang, J. W., Rodrigo, R., Felipo, V., Lubec, G., Proteome analysis of primary neurons and astrocytes from rat cerebellum. J. Proteome Res. 2005b, 4, 768-788.
127. Egnaczyk, G. F., Pomonis, J. D., Schmidt, J. A., Rogers, S. D. et al., Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics 2003, 3, 689-698.
128. Lafon-Cazal, M., Adjali, O., Galeotti, N., Poncet, J. et al., Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J. Biol. Chem. 2003, 278, 24488-24448.
129. Falsig, J., Porzgen, P., Lund, S., Schrattenholz, A., Leist, M., The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function. J. Neurochem. 2006, 96, 893-907.